FDA
-
-
-
-
-
-
-
Evercore ISI Starts vTv Therapeutics (VTVT) at Outperform, 'essentially a single-asset story'
-
-
-
-
-
-
-
vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes
-
-
-
-
-
-
-
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER
-
-
-
-
-
-
-
CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING
-
-
-
-
-
-
-
vTv Therapeutics (VTVT) Appoints Thomas Strack as Chief Medical Officer
-
-
-
-
-
-
-
CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON
-
322,199 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

